New book by Larry Connors Click here Improve your trading - See how
ratiopharm has been granted a drug identification number (DIN), along with the NOC, which will allow them under the terms of the agreement to market and distribute the product as "ratio-Amitriptyline" in the Canadian market. The process for launching the product is well along. Andrew Zaleski, Interim President and CEO of Orbus Pharma, stated; "The company is pleased with the success ratiopharm has had in filing the Abbreviated New Drug Submission (ANDS) with Health Canada. It marks the first collaboration between our two companies".
Ratiopharm inc. is a leading Canadian generic pharmaceutical company with the ability to develop, manufacture, market and distribute generic pharmaceutical products throughout Canada. The Canadian division is a subsidiary of ratiopharm GmbH, which is a large multinational generic pharmaceutical company headquartered in Germany.
Amitriptyline is an anti-depressant that is used to treat symptoms of endogenous depression. This particular depression state is more likely to be alleviated than are other depressive states. In addition to Canada, the Orbus developed product has been submitted for market authorization in selected European markets by Orbus licensees. Orbus will be manufacturing the product for both Canada and Europe at its production facility in Markham, Ontario.
Orbus Pharma Inc., headquartered in Markham, Ontario and listed on the Toronto Stock Exchange under the symbol ORB, is pursuing an integrated strategy of: (1) generic drug development, using proprietary delivery systems for certain products; (2) product out-licensing; and (3) pharmaceutical manufacturing. For more information, please visit www.orbus.ca.
Forward looking statements
Certain statements in this disclosure are "forward-looking statements", which reflect management's expectations regarding the Company's future growth, results of operations, performance and business prospects and opportunities. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Many factors could cause results to differ materially from the results discussed in the forward-looking statements, including risks related to dependence on key suppliers, economic conditions, competition, regulatory change, foreign exchange rates, and interest rates, among others. Although the forward-looking statements are based on what management believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements.
For more information contact:
Andrew B. Zaleski
Chairman and Interim President and C.E.O.
905-943-9444 ext. 229
Greg W. Muir
Vice President Finance and C.F.O.
905-943-9444 ext. 222
Email gmuir@orbus.ca
20 Konrad Crescent, Markham, Ontario, L3R 8T4
Telephone 905-943-9444, Fax 905-943-9878, Web: www.orbus.ca
Source: Orbus Pharma Inc. (TSX: ORB) http://www.orbus.ca
Maximum News Dissemination by Filing Services Canada Inc. *
www.usetdas.com
http://www.useTDAS.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
